发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
Shire Partners with Nimbus Discovery to Develop Oral Therapies for Lysosomal Storage Disorders 夏尔与Nimbus Discovery合作开发溶酶体贮积症的口服疗法
Pharmadeals Review Pub Date : 2013-05-20 DOI: 10.3833/PDR.V2013I5.1941
Heather Cartwright
{"title":"Shire Partners with Nimbus Discovery to Develop Oral Therapies for Lysosomal Storage Disorders","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I5.1941","DOIUrl":"https://doi.org/10.3833/PDR.V2013I5.1941","url":null,"abstract":"In the first deal to emerge from its tie-up with Atlas Venture, Shire has partnered with Nimbus Discovery to develop disease-altering small molecule therapies for lysosomal storage disorders (LSDs). Using its computational chemistry platform, Nimbus will profile molecules against a single disease target and will deliver a drug candidate ready to enter late preclinical studies. At this point Shire will have an exclusive option to acquire the programme. Shire already markets a portfolio of intravenously administered enzyme replacement therapies for LSDs, including Replagal® (agalsidase alpha) for Fabry disease, Vpriv® (velaglucerase alpha) for Gaucher disease and Elaprase® (idursulphase) for Hunter syndrome.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76512486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Merck & Co. Collaborates with Pfizer and Abide Therapeutics with Aim of Bolstering Diabetes Portfolio 默克公司与辉瑞公司和遵守治疗公司合作，旨在加强糖尿病产品组合
Pharmadeals Review Pub Date : 2013-05-14 DOI: 10.3833/PDR.V2013I5.1938
Heather Cartwright
{"title":"Merck & Co. Collaborates with Pfizer and Abide Therapeutics with Aim of Bolstering Diabetes Portfolio","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I5.1938","DOIUrl":"https://doi.org/10.3833/PDR.V2013I5.1938","url":null,"abstract":"Merck & Co. has formed a collaboration with Abide Therapeutics, a spin-out from The Scripps Research Institute, to discover, develop and commercialise small molecule therapies for the treatment of type 2 diabetes by targeting enzymes of the serine hydrolase class. Serine hydrolases represent one of the largest known enzyme families but are mostly under-explored as drug targets. The deal comes only days after Merck partnered with Pfizer to co-develop and co-commercialise ertugliflozin (PF-04971729), a sodium glucose co-transporter 2 (SGLT-2) inhibitor that is expected to enter Phase III development for type 2 diabetes later in 2013.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91014273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Teva Expands Respiratory Pipeline with MicroDose Therapeutx Purchase 梯瓦收购MicroDose Therapeutx扩大呼吸管道
Pharmadeals Review Pub Date : 2013-05-07 DOI: 10.3833/PDR.V2013I7.1961
Heather Cartwright
{"title":"Teva Expands Respiratory Pipeline with MicroDose Therapeutx Purchase","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1961","DOIUrl":"https://doi.org/10.3833/PDR.V2013I7.1961","url":null,"abstract":"Teva Pharmaceutical Industries has agreed to acquire MicroDose Therapeutx and its proprietary inhalation technologies for US$40 M upfront and up to US$125 M in post-acquisition milestones. MicroDose’s pipeline of products for lung diseases and infections is led by MDT-637, an inhalable small molecule fusion inhibitor that prevents replication of the respiratory syncytial virus and which is expected to begin Phase II trials later in 2013. The deal complements Teva’s therapeutic focus on respiratory and CNS diseases as part of a revised growth strategy outlined in December 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85525651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valeant Increases Offer for Obagi Medical Products After Merz Pharma Bid 在Merz制药出价后，Valeant提高了对Obagi医疗产品的报价
Pharmadeals Review Pub Date : 2013-05-04 DOI: 10.3833/PDR.V2013I4.1917
Heather Cartwright
{"title":"Valeant Increases Offer for Obagi Medical Products After Merz Pharma Bid","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1917","DOIUrl":"https://doi.org/10.3833/PDR.V2013I4.1917","url":null,"abstract":"Valeant Pharmaceuticals International has made a sweetened offer to acquire Obagi Medical Products, a California-based developer of physician-dispensed skincare systems, for US$24 per share. The company revised its March 2013 offer of US$19.75 per share after Obagi received an unsolicited bid of US$22 per share from Germany’s Merz Pharma. The Board of Directors of Obagi has approved the revised offer, which values the company at approximately US$418 M. Valeant has built its dermatology franchise via M&A, most notably acquiring Medicis Pharmaceutical for US$2.6 B in December 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83521588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration 罗氏与爱思利康合作加强对中国HCV市场的关注
Pharmadeals Review Pub Date : 2013-04-23 DOI: 10.3833/PDR.V2013I4.1927
Heather Cartwright
{"title":"Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1927","DOIUrl":"https://doi.org/10.3833/PDR.V2013I4.1927","url":null,"abstract":"Roche has partnered with the US- and China-based speciality pharmaceutical company Ascletis for the development and commercialisation of its hepatitis C virus (HCV) protease inhibitor danoprevir in China. At present, no direct-acting antiviral agents are available for the treatment of HCV in the country. Roche acquired the drug candidate from InterMune in 2010 and subsequently chose to pursue its development as an add-on therapy to Pegasys® (peginterferon alpha-2a) in emerging markets. Ascletis will fund and be responsible for the development, regulatory affairs and manufacturing of danoprevir in greater China, including Taiwan, Hong Kong and Macau.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"230 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76928883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator 辉瑞成为BIND Therapeutics的第二个主要纳米医学合作伙伴
Pharmadeals Review Pub Date : 2013-04-16 DOI: 10.3833/PDR.V2013I4.1924
Heather Cartwright
{"title":"Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1924","DOIUrl":"https://doi.org/10.3833/PDR.V2013I4.1924","url":null,"abstract":"BIND Therapeutics, which is developing a new class of targeted and programmable therapeutics called Accurins™, has secured its second big pharma partner. The company has formed a collaboration with Pfizer to utilise its Medicinal Nanoengineering® platform to develop and commercialise multiple Accurins using select small molecule targeted therapies supplied by Pfizer. BIND formed a similar collaboration with Amgen in January 2013 and will use the payments it receives from the two partnerships to fund a Phase II clinical programme for its lead drug candidate BIND-014 in multiple solid tumours.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"200 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85612426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Merck & Co. Changes Tack on Biosimilars with Samsung Bioepis Collaboration 默克公司与三星Bioepis合作改变生物仿制药策略
Pharmadeals Review Pub Date : 2013-02-28 DOI: 10.3833/PDR.V2013I2.1904
Heather Cartwright
{"title":"Merck & Co. Changes Tack on Biosimilars with Samsung Bioepis Collaboration","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I2.1904","DOIUrl":"https://doi.org/10.3833/PDR.V2013I2.1904","url":null,"abstract":"Merck & Co. has formed a partnership with Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, to develop and market multiple biosimilar candidates. Samsung Bioepis will assume responsibility for the development, manufacturing and registration of the biosimilars, while Merck will be responsible for commercialisation activities. The deal represents a change in strategy for Merck, which has faced a number of setbacks in the development of biosimilars in recent years and which integrated Merck BioVentures, its independent biosimilars unit, into the biologics and vaccines division of Merck Research Laboratories in 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86622446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant 卫材将CTCL治疗药物Targretin®的美国权利转让给Valeant
Pharmadeals Review Pub Date : 2013-02-28 DOI: 10.3833/PDR.V2013I2.1905
Heather Cartwright
{"title":"Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I2.1905","DOIUrl":"https://doi.org/10.3833/PDR.V2013I2.1905","url":null,"abstract":"Valeant Pharmaceuticals International has acquired US rights to the capsule and gel formulations of Targretin® (bexarotene), which is used to treat skin problems arising from cutaneous T-cell lymphoma, from Eisai for US$65 M upfront plus contingent payments based on certain undisclosed milestones. Eisai, which acquired Targretin from Ligand Pharmaceuticals in 2006, will retain rights outside of the US and will continue to supply product to its sales subsidiaries and distribution partners.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78995778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review of Deal Making in 2012 2012年并购交易回顾
Pharmadeals Review Pub Date : 2013-02-26 DOI: 10.3833/PDR.V2013I2.1903
Heather Cartwright
{"title":"A Review of Deal Making in 2012","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I2.1903","DOIUrl":"https://doi.org/10.3833/PDR.V2013I2.1903","url":null,"abstract":"Deal activity in the pharmaceutical industry fell notably in 2012 as partnering strategies became increasingly focused and R&D budgets remained constrained. Mean deal values increased from 2011, however, and upfront payments remained robust as licensing continued to represent an important source of non-dilutive funding for biotech companies in a still challenging financing climate. Bolt-on acquisitions were the order of the day and some of the highest valuations were reserved for mature biotechs with late-stage or marketed products. Oncology continued to dominate the deal-making landscape and GlaxoSmithKline overtook Roche to become the most prolific dealmaker.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78554263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Biocon Finds a New Partner for its Biosimilar Insulin Analogues in Mylan Biocon为其胰岛素类似物在Mylan找到了新的合作伙伴
Pharmadeals Review Pub Date : 2013-02-26 DOI: 10.3833/PDR.V2013I2.1901
Heather Cartwright
{"title":"Biocon Finds a New Partner for its Biosimilar Insulin Analogues in Mylan","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I2.1901","DOIUrl":"https://doi.org/10.3833/PDR.V2013I2.1901","url":null,"abstract":"Mylan has formed a global collaboration with the Indian biotech Biocon to develop and commercialise biosimilar versions of three insulin analogues: Sanofi’s Lantus® (glargine), Eli Lilly’s Humalog® (lispro) and Novo Nordisk’s NovoLog® (aspart). Together these products generated combined net sales of approximately US$11.5 B in 2012. Biocon was in need of a global partner for its biosimilar insulin programmes, which until March 2012 were licensed to Pfizer. Biocon and Mylan have an existing collaboration for the development and commercialisation of five high-value generic biologics.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77296575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信